Skip to main content
SpringerLink
Log in

VHL: Trends and Insight into a Multi-Modality, Interdisciplinary Approach for Management of Central Nervous System Hemangioblastoma

  • Chapter
  • First Online:
The Funnel: From the Skull Base to the Sacrum

Part of the book series: Acta Neurochirurgica Supplement ((NEUROCHIRURGICA,volume 135))

  • 334 Accesses

Abstract

Von Hippel-Lindau (VHL) is a multi-system disease which results in significant morbidity from central nervous system (CNS) involvement as well as ocular, renal and neuro-endocrine effects. Haemangioblastomas of the CNS present a number of challenges. The natural history of these lesions is varied, as is the size and location within the CNS. Whilst surgery is considered the mainstay of treatment and best chance at curing these lesions, this is also often associated with significant risks due to the anatomical location of these lesions, most commonly the posterior fossa and spinal cord.

We review the literature and describe our experience across two separate European VHL referral centres. Alternative treatment options and combined modalities are increasingly being used in the context of managing CNS haemangioblastomas. We analyse the increasing use of stereotactic radiosurgery and the evolution of medical treatments as potential future adjuncts to surgery. The availability of multiple modalities in our armamentarium is essential in tailoring a personalised treatment approach to these patients. Owing to the multi-systemic nature of the disease, in our experience, managing the care of patients with VHL is best delivered using an interdisciplinary approach utilising multiple specialties and adopting an individually tailored holistic approach.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Schunemann V, Huntoon K, Lonser RR. Personalized medicine for nervous system manifestations of von Hippel-Lindau disease. Front Surg. 2016;3:39.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature. 1988;332(6161):268–9.

    Article  CAS  PubMed  Google Scholar 

  3. Clifford SC, Cockman ME, Smallwood AC, Mole DR, et al. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet. 2001;10(10):1029–38.

    Article  CAS  PubMed  Google Scholar 

  4. Hoffman MA, Ohh M, Yang H, Klco JM, et al. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet. 2001;10(10):1019–27.

    Article  CAS  PubMed  Google Scholar 

  5. Zbar B, Kishida T, Chen F, Schmidt L, et al. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat. 1996;8(4):348–57.

    Article  CAS  PubMed  Google Scholar 

  6. Lonser RR, Butman JA, Huntoon K, Asthagiri AR, et al. Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease. J Neurosurg. 2014;120(5):1055–62.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Maher ER, Yates JR, Harries R, Benjamin C, et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med. 1990;77(283):1151–63.

    Article  CAS  PubMed  Google Scholar 

  8. Neumann HP, Eggert HR, Weigel K, Friedburg H, et al. Hemangioblastomas of the central nervous system. A 10-year study with special reference to von Hippel-Lindau syndrome. J Neurosurg. 1989;70(1):24–30.

    Article  CAS  PubMed  Google Scholar 

  9. GLASKER, S. Central nervous system manifestations in VHL: genetics, pathology and clinical phenotypic features. Familial Cancer. 2005;4(1):37–42.

    Article  PubMed  Google Scholar 

  10. Gläsker S, Bender BU, Apel TW, Natt E, et al. The impact of molecular genetic analysis of the VHL gene in patients with haemangioblastomas of the central nervous system. J Neurol Neurosurg Psychiatry. 1999;67(6):758–62.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Ho VB, Smirniotopoulos JG, Murphy FM, Rushing EJ. Radiologic-pathologic correlation: hemangioblastoma. AJNR Am J Neuroradiol. 1992;13(5):1343–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Neumann HP, Eggert HR, Scheremet R, Schumacher M, et al. Central nervous system lesions in von Hippel-Lindau syndrome. J Neurol Neurosurg Psychiatry. 1992;55(10):898–901.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Migliorini D, Haller S, Merkler D, Pugliesi-Rinaldi A, et al. Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review. CNS Oncol. 2015;4(6):387–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Thompson LD. Endolymphatic sac tumor. Ear Nose Throat J. 2013;92(4–5):184–8.

    Article  PubMed  Google Scholar 

  15. Ba-Abbad RA, Nowilaty SR. Bilateral optic disc swelling as the presenting sign of pheochromocytoma in a child. Medscape J Med. 2008;10(7):176.

    PubMed  PubMed Central  Google Scholar 

  16. Shah V, Zlotcavitch L, Herro AM, Dubovy SR, et al. Bilateral papillopathy as a presenting sign of pheochromocytoma associated with von Hippel-Lindau disease. Clin Ophthalmol. 2014;8:623–8.

    PubMed  PubMed Central  Google Scholar 

  17. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915–42.

    Article  CAS  PubMed  Google Scholar 

  18. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271–5.

    Article  CAS  PubMed  Google Scholar 

  19. Elvidge GP, Glenny L, Appelhoff RJ, Ratcliffe PJ, et al. Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways. J Biol Chem. 2006;281(22):15215–26.

    Article  CAS  PubMed  Google Scholar 

  20. Schödel J, Oikonomopoulos S, Ragoussis J, PUGH CW, et al. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood. 2011;117(23):e207–17.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Levy AP, Levy NS, Goldberg MA. Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein. J Biol Chem. 1996;271(41):25492–7.

    Article  CAS  PubMed  Google Scholar 

  22. Schraml P, Struckmann K, Hatz F, Sonnet S, et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol. 2002;196(2):186–93.

    Article  CAS  PubMed  Google Scholar 

  23. Brauch H, Weirich G, Brieger J, Glavac D, et al. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res. 2000;60(7):1942–8.

    CAS  PubMed  Google Scholar 

  24. Patard JJ, Fergelot P, Karakiewicz PI, Klatte T, et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer. 2008;123(2):395–400.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Carlessi R, Chen Y, Rowlands J, Cruzat VF, et al. GLP-1 receptor signalling promotes β-cell glucose metabolism via mTOR-dependent HIF-1α activation. Sci Rep. 2017;7(1):2661.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Van de Velde S, Hogan MF, Montminy M. mTOR links incretin signaling to HIF induction in pancreatic beta cells. Proc Natl Acad Sci U S A. 2011;108(41):16876–82.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Jin X, Dai L, Ma Y, Wang J, et al. Implications of HIF-1α in the tumorigenesis and progression of pancreatic cancer. Cancer Cell Int. 2020;20:273.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Ammerman JM, Lonser RR, Dambrosia J, Butman JA, et al. Long-term natural history of hemangioblastomas in patients with von Hippel-Lindau disease: implications for treatment. J Neurosurg. 2006;105(2):248–55.

    Article  PubMed  Google Scholar 

  29. Asthagiri AR, Mehta GU, Zach L, Li X, et al. Prospective evaluation of radiosurgery for hemangioblastomas in von Hippel-Lindau disease. Neuro-Oncology. 2010;12(1):80–6.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Wanebo JE, Lonser RR, Glenn GM, Oldfield EH. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg. 2003;98(1):82–94.

    Article  PubMed  Google Scholar 

  31. Resche F, Moisan JP, Mantoura J, de Kersaint-Gilly A, et al. Haemangioblastoma, haemangioblastomatosis, and von Hippel-Lindau disease. Adv Tech Stand Neurosurg. 1993;20:197–304.

    Article  CAS  PubMed  Google Scholar 

  32. Weil RJ, Lonser RR, Devroom HL, Wanebo JE, et al. Surgical management of brainstem hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg. 2003;98(1):95–105.

    Article  PubMed  Google Scholar 

  33. Van Velthoven V, Reinacher PC, Klisch J, Neumann HP, et al. Treatment of intramedullary hemangioblastomas, with special attention to von Hippel-Lindau disease. Neurosurgery. 2003;53(6):1306–13; discussion 1313-1304

    Article  PubMed  Google Scholar 

  34. Smalley SR, Schomberg PJ, Earle JD, Laws ER, et al. Radiotherapeutic considerations in the treatment of hemangioblastomas of the central nervous system. Int J Radiat Oncol Biol Phys. 1990;18(5):1165–71.

    Article  CAS  PubMed  Google Scholar 

  35. Hojo M, Arakawa Y, Funaki T, Yoshida K, et al. Usefulness of tumor blood flow imaging by intraoperative indocyanine green videoangiography in hemangioblastoma surgery. World Neurosurg. 2014;82(3–4):e495–501.

    Article  PubMed  Google Scholar 

  36. Molina CA, Pennington Z, Ahmed AK, Westbroek E, et al. Use of intraoperative indocyanine green angiography for feeder vessel ligation and en bloc resection of intramedullary hemangioblastoma. Oper Neurosurg (Hagerstown). 2019;17(6):573–9.

    Article  PubMed  Google Scholar 

  37. Tamura Y, Hirota Y, Miyata S, Yamada Y, et al. The use of intraoperative near-infrared indocyanine green videoangiography in the microscopic resection of hemangioblastomas. Acta Neurochir. 2012;154(8):1407–12; discussion 1412.

    Article  PubMed  Google Scholar 

  38. Herrmann HD, Neuss M, Winkler D. Intramedullary spinal cord tumors resected with CO2 laser microsurgical technique: recent experience in fifteen patients. Neurosurgery. 1988;22(3):518–22.

    Article  CAS  PubMed  Google Scholar 

  39. Eskridge JM, Mcauliffe W, Harris B, Kim DK, et al. Preoperative endovascular embolization of craniospinal hemangioblastomas. AJNR Am J Neuroradiol. 1996;17(3):525–31.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Tampieri D, Leblanc R, Terbrugge K. Preoperative embolization of brain and spinal hemangioblastomas. Neurosurgery. 1993;33(3):502–5; discussion 505.

    CAS  PubMed  Google Scholar 

  41. Vázquez-Añón V, Botella C, Beltrán A, Solera M, et al. Preoperative embolization of solid cervicomedullary junction hemangioblastomas: report of two cases. Neuroradiology. 1997;39(2):86–9.

    Article  PubMed  Google Scholar 

  42. Ene CI, Xu D, Morton RP, Emerson S, et al. Safety and efficacy of preoperative embolization of intracranial hemangioblastomas. Oper Neurosurg (Hagerstown). 2016;12(2):135–40.

    Article  PubMed  Google Scholar 

  43. Pan J, Ho AL, D'Astous M, Sussman ES, et al. Image-guided stereotactic radiosurgery for treatment of spinal hemangioblastoma. Neurosurg Focus. 2017;42(1):E12.

    Article  PubMed  Google Scholar 

  44. Niemelä M, Lim YJ, Söderman M, Jääskeläinen J, et al. Gamma knife radiosurgery in 11 hemangioblastomas. J Neurosurg. 1996;85(4):591–6.

    Article  PubMed  Google Scholar 

  45. Richard S, Campello C, Taillandier L, Parker F, et al. Haemangioblastoma of the central nervous system in von Hippel-Lindau disease. French VHL study group. J Intern Med. 1998;243(6):547–53.

    Article  CAS  PubMed  Google Scholar 

  46. Chakraborti PR, Chakrabarti KB, Doughty D, Plowman PN. Stereotactic multiple are radiotherapy. IV--Haemangioblastoma. Br J Neurosurg. 1997;11(2):110–5.

    Article  CAS  PubMed  Google Scholar 

  47. Bartoš R, Lodin J, Marek T, Sameš M, et al. Combined treatment of a medulla oblongata hemangioblastoma via permanent cysto-cisternal drainage and (postponed) gamma knife radiosurgery: a case report and review of the literature. Int J Neurosci. 2020;132:1–5.

    Google Scholar 

  48. Hanakita S, Koga T, Shin M, Takayanagi S, et al. The long-term outcomes of radiosurgery for intracranial hemangioblastomas. Neuro-Oncology. 2014;16(3):429–33.

    Article  PubMed  Google Scholar 

  49. Kong X, Lin Z, Liang D, Fath D, et al. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol. 2006;26(6):2019–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Further Reading

  1. Ben-Skowronek I, Kozaczuk S. Von Hippel-Lindau syndrome. Horm Res Paediatr. 2015;84(3):145–52.

    Article  CAS  PubMed  Google Scholar 

  2. Sung DI, Chang CH, Harisiadis L. Cerebellar hemangioblastomas. Cancer. 1982;49(3):553–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Barts Health NHS Trust, London, UK

    S. A. Matloob & D. Paraskevopoulos

  2. Department of Neurosurgery, Royal London Hospital, London, UK

    S. A. Matloob

  3. Department of Endocrinology, The Royal Hallamshire Hospital, Sheffield, UK

    S. M. O’Toole

  4. Department of Endocrinology, Barts Health NHS Trust, London, UK

    W. Drake

  5. Department of Oncology, Barts Health NHS Trust, London, UK

    N. Plowman

  6. Department of Neurosurgery, AHEPA University Hospital, Thessaloniki, Greece

    N. Foroglou

Authors
  1. S. A. Matloob
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Paraskevopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. M. O’Toole
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W. Drake
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Plowman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N. Foroglou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. A. Matloob .

Editor information

Editors and Affiliations

  1. Institute of Neurosurgery, Catholic University of Rome, Rome, Italy

    Massimiliano Visocchi

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Matloob, S.A., Paraskevopoulos, D., O’Toole, S.M., Drake, W., Plowman, N., Foroglou, N. (2023). VHL: Trends and Insight into a Multi-Modality, Interdisciplinary Approach for Management of Central Nervous System Hemangioblastoma. In: Visocchi, M. (eds) The Funnel: From the Skull Base to the Sacrum. Acta Neurochirurgica Supplement, vol 135. Springer, Cham. https://doi.org/10.1007/978-3-031-36084-8_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-36084-8_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-36083-1

  • Online ISBN: 978-3-031-36084-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation